These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
624 related articles for article (PubMed ID: 36990794)
1. [Contribution of serotonin 5-HT Ibi D Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794 [TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD). Olivier B; Olivier JDA Adv Exp Med Biol; 2024; 1456():49-66. PubMed ID: 39261423 [TBL] [Abstract][Full Text] [Related]
3. [Up-to-Date on clinical and preclinical studies of psilocybin therapy]. Ibi D Nihon Yakurigaku Zasshi; 2024; 159(4):214-218. PubMed ID: 38945903 [TBL] [Abstract][Full Text] [Related]
4. Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice. Takaba R; Ibi D; Yoshida K; Hosomi E; Kawase R; Kitagawa H; Goto H; Achiwa M; Mizutani K; Maeda K; González-Maeso J; Kitagaki S; Hiramatsu M Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3019-3035. PubMed ID: 37874338 [TBL] [Abstract][Full Text] [Related]
5. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT Sekssaoui M; Bockaert J; Marin P; Bécamel C Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441 [TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; Rosenblat JD; Castle D; McIntyre RS CNS Drugs; 2022 Jan; 36(1):17-30. PubMed ID: 34791625 [TBL] [Abstract][Full Text] [Related]
7. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. Dos Santos RG; Hallak JE; Baker G; Dursun S J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877 [TBL] [Abstract][Full Text] [Related]
8. Psilocybin and Other Classic Psychedelics in Depression. Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D Curr Top Behav Neurosci; 2024; 66():149-174. PubMed ID: 37955822 [TBL] [Abstract][Full Text] [Related]
9. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555 [TBL] [Abstract][Full Text] [Related]
10. New investigational agents for the treatment of major depressive disorder. Pochwat B; Krupa AJ; Siwek M; Szewczyk B Expert Opin Investig Drugs; 2022 Oct; 31(10):1053-1066. PubMed ID: 35975761 [TBL] [Abstract][Full Text] [Related]
11. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Le GH; Wong S; Badulescu S; Au H; Di Vincenzo JD; Gill H; Phan L; Rhee TG; Ho R; Teopiz KM; Kwan ATH; Rosenblat JD; Mansur RB; McIntyre RS J Affect Disord; 2024 Jun; 355():342-354. PubMed ID: 38570038 [TBL] [Abstract][Full Text] [Related]
12. The possible place for psychedelics in pharmacotherapy of mental disorders. Wojtas A Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320 [TBL] [Abstract][Full Text] [Related]
13. Next generation antidepressants with novel mechanisms for treatment resistant depression. Chen MH; Tu PC; Su TP Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491 [TBL] [Abstract][Full Text] [Related]
14. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301 [TBL] [Abstract][Full Text] [Related]
15. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835 [TBL] [Abstract][Full Text] [Related]
16. Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics? Hashimoto K Eur Arch Psychiatry Clin Neurosci; 2024 Feb; ():. PubMed ID: 38411629 [TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962 [TBL] [Abstract][Full Text] [Related]
18. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. van den Berg M; Magaraggia I; Schreiber R; Hillhouse TM; Porter JH Psychopharmacology (Berl); 2022 Jun; 239(6):1853-1879. PubMed ID: 35348806 [TBL] [Abstract][Full Text] [Related]
19. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748 [TBL] [Abstract][Full Text] [Related]
20. Psychedelics for treatment resistant depression: are they game changers? Kalfas M; Taylor RH; Tsapekos D; Young AH Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]